Most Recent
Hundreds of women who suffered “chaos and devastation” at the hands of former surgeon Emil Gayed will be entitled to compensation after class action law firm Slater & Gordon negotiated with the state government to secure a redress scheme.
Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.
Botox maker Allergan has successfully challenged a Federal Court judgment dismissing its trade mark lawsuit against an Australian company selling topical creams as an alternative to Botox injections.
Avant Insurance has launched an appeal of a Federal Court judgment ordering it to cover the defence costs of a surgeon facing a class action by breast implant patients of defunct clinic the Cosmetic Institute.
Tens of thousands of hospital patients were put at risk when Medtronic unlawfully supplied a bone grafting kit to hospitals that was not registered on the Australian Register of Therapeutic Goods, according to new regulatory proceedings.
The Commissioner of Patents has appealed a landmark judgment that found artificial intelligence can be named an inventor on a patent application.
Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an "untenable" patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.
Multinational health technology company Philips may be hit with a class action after its sleep therapy machines were subject to an urgent safety recall over concerns customers could inhale degrading foam.
Swiss pharmaceutical company Biogen has filed another lawsuit accusing an Australian generic drug manufacturer of infringing the patent for its blockbuster multiple sclerosis drug Tecfidera.